Anorexia

Treatment options for patients with advanced cancer

Aminah Jatoi, Phuong L. Nguyen

Research output: Contribution to journalArticle

Abstract

In patients with advanced cancer, anorexia, or loss of appetite, is prevalent, distressing, and predictive of a poor prognosis. Patients with cancer who are receiving antineoplastic treatment experience this symptom, as do patients with cancer who are no longer receiving such therapy. Yet palliative options remain limited. The two most frequently used palliative measures employ progestational agents and corticosteroids. Both classes of agents provide only modest clinical benefits. Recent studies suggest promising results with melatonin, blockade of tumor necrosis factor-α, necrosis factor-κ B decoys, adenosine triphosphate, antiemetics, and anti-inflammatory agents. These agents appear promising, but further clinical research is needed before they can be prescribed outside clinical trial settings.

Original languageEnglish (US)
Pages (from-to)269-275
Number of pages7
JournalAmerican Journal of Cancer
Volume1
Issue number4
DOIs
StatePublished - 2002

Fingerprint

Anorexia
Neoplasms
Antiemetics
Appetite
Progestins
Melatonin
Antineoplastic Agents
Adrenal Cortex Hormones
Anti-Inflammatory Agents
Necrosis
Therapeutics
Tumor Necrosis Factor-alpha
Adenosine Triphosphate
Clinical Trials
Research

ASJC Scopus subject areas

  • Oncology

Cite this

Anorexia : Treatment options for patients with advanced cancer. / Jatoi, Aminah; Nguyen, Phuong L.

In: American Journal of Cancer, Vol. 1, No. 4, 2002, p. 269-275.

Research output: Contribution to journalArticle

@article{bdc4c02e7d0c439fae6f7ec987dd53a6,
title = "Anorexia: Treatment options for patients with advanced cancer",
abstract = "In patients with advanced cancer, anorexia, or loss of appetite, is prevalent, distressing, and predictive of a poor prognosis. Patients with cancer who are receiving antineoplastic treatment experience this symptom, as do patients with cancer who are no longer receiving such therapy. Yet palliative options remain limited. The two most frequently used palliative measures employ progestational agents and corticosteroids. Both classes of agents provide only modest clinical benefits. Recent studies suggest promising results with melatonin, blockade of tumor necrosis factor-α, necrosis factor-κ B decoys, adenosine triphosphate, antiemetics, and anti-inflammatory agents. These agents appear promising, but further clinical research is needed before they can be prescribed outside clinical trial settings.",
author = "Aminah Jatoi and Nguyen, {Phuong L.}",
year = "2002",
doi = "10.2165/00024669-200201040-00004",
language = "English (US)",
volume = "1",
pages = "269--275",
journal = "American Journal of Cancer",
issn = "1175-6357",
publisher = "Adis International Ltd",
number = "4",

}

TY - JOUR

T1 - Anorexia

T2 - Treatment options for patients with advanced cancer

AU - Jatoi, Aminah

AU - Nguyen, Phuong L.

PY - 2002

Y1 - 2002

N2 - In patients with advanced cancer, anorexia, or loss of appetite, is prevalent, distressing, and predictive of a poor prognosis. Patients with cancer who are receiving antineoplastic treatment experience this symptom, as do patients with cancer who are no longer receiving such therapy. Yet palliative options remain limited. The two most frequently used palliative measures employ progestational agents and corticosteroids. Both classes of agents provide only modest clinical benefits. Recent studies suggest promising results with melatonin, blockade of tumor necrosis factor-α, necrosis factor-κ B decoys, adenosine triphosphate, antiemetics, and anti-inflammatory agents. These agents appear promising, but further clinical research is needed before they can be prescribed outside clinical trial settings.

AB - In patients with advanced cancer, anorexia, or loss of appetite, is prevalent, distressing, and predictive of a poor prognosis. Patients with cancer who are receiving antineoplastic treatment experience this symptom, as do patients with cancer who are no longer receiving such therapy. Yet palliative options remain limited. The two most frequently used palliative measures employ progestational agents and corticosteroids. Both classes of agents provide only modest clinical benefits. Recent studies suggest promising results with melatonin, blockade of tumor necrosis factor-α, necrosis factor-κ B decoys, adenosine triphosphate, antiemetics, and anti-inflammatory agents. These agents appear promising, but further clinical research is needed before they can be prescribed outside clinical trial settings.

UR - http://www.scopus.com/inward/record.url?scp=0042885368&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0042885368&partnerID=8YFLogxK

U2 - 10.2165/00024669-200201040-00004

DO - 10.2165/00024669-200201040-00004

M3 - Article

VL - 1

SP - 269

EP - 275

JO - American Journal of Cancer

JF - American Journal of Cancer

SN - 1175-6357

IS - 4

ER -